• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Leap Therapeutics Inc.

    3/26/25 5:01:13 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LPTX alert in real time by email
    S-8 1 tm2510101d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on March 26, 2025

     

    Registration No. 333-               

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    Leap Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 27-4412575
    (State or other jurisdiction of
    incorporation or organization)
    (IRS Employer
    Identification No.)

     

    47 Thorndike Street

    Suite B1-1

    Cambridge, MA 02141

    Telephone: (617) 714-0360

    (Address of principal executive offices) (Zip Code)

     

    Leap Therapeutics, Inc. 2016 Equity Incentive Plan

    (Full title of the Plan)

     

     

    Douglas E. Onsi

    Chief Executive Officer and President

    Leap Therapeutics, Inc.

    47 Thorndike Street, Suite B1-1

    Cambridge, MA 02141

    (Name and address of agent for service)

     

    (617) 714-0360

    (Telephone number, including area code, of agent for service)

     

     

    Copy to:

    Julio E. Vega, Esq.

    Morgan, Lewis & Bockius LLP

    One Federal Street

    Boston, MA 02110

    (617) 951-8000

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
       
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    INCORPORATION OF DOCUMENTS BY REFERENCE

     

    This Registration Statement on Form S-8, relating to the Leap Therapeutics, Inc. 2016 Equity Incentive Plan, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of the following Registration Statements on Form S-8 previously filed by the Registrant with the Securities and Exchange Commission (the “Commission”):

     

    ·Registration Statement on Form S-8, File No. 333-215787, filed on January 27, 2017;

     

    ·Registration Statement on Form S-8, File No. 333-223707, filed on March 16, 2018;

     

    ·Registration Statement on Form S-8, File No. 333-232066, filed on June 11, 2019;

     

    ·Registration Statement on Form S-8, File No. 333-237295, filed on March 20, 2020;

     

    ·Registration Statement on Form S-8, File No. 333-254360, filed on March 16, 2021;

     

    ·Registration Statement on Form S-8, File No. 333-262409, filed on January 28, 2022;

     

    ·Registration Statement on Form S-8, File No. 333-269586, filed on February 6, 2023; and

     

    ·Registration Statement on Form S-8, File No. 333-276726, filed on January 26, 2024.

     

     

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.Exhibits.

     

    Exhibit Number Exhibit

     

    4.1Fourth Amended and Restated Certificate of Incorporation of Leap Therapeutics, Inc. (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K as filed on September 10, 2020).
    4.2Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Leap Therapeutics, Inc. dated June 20, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q as filed on November 13, 2023).
    4.3Certificate of Elimination of the Series X Non-Voting Convertible Preferred Stock of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q as filed on November 13, 2023).
    4.4Amended and Restated By-laws of Leap Therapeutics, Inc. (incorporated by reference to Exhibit 3.4 to the Registrant's registration statement on Form S-4 as filed on September 26, 2016 and attached as Annex D to the prospectus which forms part of such registration statement).
    4.5Form of Common Stock Certificate of the Registrant (filed as Exhibit 4.1 to Amendment No. 2 to the Registrant’s registration statement on Form S-4 as filed on November 16, 2016).
    5.1 Opinion of Morgan, Lewis & Bockius LLP.
    23.1Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm.
    23.2Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1).
    24.1 Powers of Attorney (included on the signature page of this Form S-8).
    99.1Leap Therapeutics, Inc. 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the registration statement on Form S-8 filed with the Commission on January 27, 2017).
    99.2First Amendment to the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the registration statement on Form S-8 filed with the Commission on June 11, 2019).
    107 Filing Fee Table

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts on March 26, 2025.

     

      LEAP THERAPEUTICS, INC.
       
      By: /s/ Douglas E. Onsi
      Name: Douglas E. Onsi
      Title: Chief Executive Officer and President

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christopher Mirabelli and Douglas Onsi, and each of them, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
    /s/ Douglas E. Onsi   Chief Executive Officer, President, Chief Financial Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer)   March 26, 2025
    Douglas E. Onsi        
             
    /s/ Christopher K. Mirabelli   Director and Chair   March 26, 2025
    Christopher K. Mirabelli        
             
    /s/ James Cavanaugh   Director   March 26, 2025
    James Cavanaugh        
             
    /s/ Thomas Dietz   Director   March 26, 2025
    Thomas Dietz        
             
    /s/ William Li   Director   March 26, 2025
    William Li        
             
    /s/ Joseph Loscalzo   Director   March 26, 2025
    Joseph Loscalzo        
             
    /s/ Patricia Martin   Director   March 26, 2025
    Patricia Martin        
             
    /s/ Nissim Mashiach   Director   March 26, 2025
    Nissim Mashiach        
             
    /s/ Christian Richard   Director   March 26, 2025
    Christian Richard        
             
    /s/ Richard L. Schilsky   Director   March 26, 2025
    Richard L. Schilsky        

     

     

    Get the next $LPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LPTX

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Neutral
    H.C. Wainwright
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    6/28/2024$8.00Buy
    Rodman & Renshaw
    10/4/2021$6.00Buy
    Mizuho
    9/14/2021$3.00 → $4.00Outperform
    Raymond James
    More analyst ratings

    $LPTX
    Financials

    Live finance-specific insights

    See more
    • Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024. Leap Highlights: Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (P

      3/26/25 7:05:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

      Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, g

      3/26/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

      35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Jan.

      1/28/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E converted options into 32,500 shares, increasing direct ownership by 44% to 106,146 units (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:55:11 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Head of Reg Affairs/Qual Granfield Christine converted options into 22,500 shares and covered exercise/tax liability with 6,604 shares (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:54:08 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Baum Jason covered exercise/tax liability with 6,604 shares and converted options into 22,500 shares (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:53:26 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Leap Therapeutics Reports First Quarter 2025 Financial Results

      CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) patients demonstrating significantly higher overall response rate (ORR) and longer progression-free survival (PFS) across DKK1-high and VEGF-naïve subgroupsHosted virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, to further discuss the

      5/13/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Shai Lankry as Chief Financial Officer

      U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke

      5/12/25 7:30:00 AM ET
      $GMDA
      $LPTX
      $PPBT
      $WST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

      FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. FL-501 is a potential best-in-class monoclonal antibody targeting growth differentiation factor 15 (GDF-15), a cytokine that is impli

      4/25/25 1:00:00 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    SEC Filings

    See more
    • Leap Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      5/13/25 7:10:27 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Leap Therapeutics Inc.

      10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      5/13/25 6:51:44 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Leap Therapeutics Inc.

      DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      4/25/25 8:54:12 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      11/14/24 6:07:56 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      4/25/24 8:39:23 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      4/19/24 4:31:26 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leap Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

      1/29/25 7:15:39 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

      1/29/25 7:15:19 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Leap Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00

      6/28/24 8:18:39 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

      CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a

      9/6/22 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care